Schizophrenia’s strongest known genetic risk deconstructed

Suspect gene may trigger runaway synaptic pruning during adolescence – NIH-funded study Versions of a gene linked to schizophrenia may trigger runaway pruning of the teenage brain’s still-maturing communications infrastructure, NIH-funded researchers have discovered.  People with the illness show fewer such connections between neurons, or synapses.  The gene switched on more in people with the suspectRead More

[Continue reading…]

How do your symptoms affect your day?

Sardaa Health Storylines

Do your symptoms have an impact on your day? Whether it’s fatigue, headaches, or nausea; symptoms have the power to affect your overall state of mind and wellbeing. Don’t let this go undocumented. When reporting your symptoms into your SARDAA Health Storylines app, remember to note how the symptoms impacted your day. Sometimes it’sRead More

[Continue reading…]

Help NIMH Raise Awareness for Clinical Research on Social Media

Please join NIMH’s Thunderclap to help raise awareness about the importance of clinical research for understanding and treating mental illnesses through social media. After you sign up for the Thunderclap, the following message will automatically be sent to your social media accounts at 7:00 PM ET on February 21, 2016: “Clinical research is our best hopeRead More

[Continue reading…]

Team-based Treatment for First Episode Psychosis Found to be High Value

NIH-funded study shows early intervention is more cost-effective than typical care. New analysis from a mental health care study shows that “coordinated specialty care” (CSC) for young people with first episode psychosis is more cost-effective than typical community care. Cost-effectiveness analysis in health care is a way to compare the costs and benefits of twoRead More

[Continue reading…]

Want to Help the FDA? Become a Consumer Representative on an FDA Advisory Committee

Have you ever wanted to be part of the food and drug regulatory process? Do you have a history of public interest or a passion for consumer advocacy? Do you have experience analyzing scientific data? If you answered “Yes,” here’s your opportunity to become an advocate for consumers! The Food and Drug Administration continually seeksRead More

[Continue reading…]

RESEARCH WEEKLY: How RAISE Models Work in Early Psychosis

The goal of the NIMH-funded project called RAISE – Recovery After Initial Schizophrenic Episode – was to develop and test a “real world” early-intervention approach that would work in the fragmented US health care system to change the course and prognosis of psychotic disorders. Other countries had been using coordinated first-episode models with good resultsRead More

[Continue reading…]

Opening schizophrenia’s black box Broad Institute

Print PDF

[Continue reading…]

Looking for more with SARDAA Health Storylines? Add a tool!

Did you know that there are more options to enhance your SARDAA Health Storylines app? Make it your own by personalizing your app to best meet your care needs. Add the tools to your dashboard that help you improve your daily life. Simply go on to your SARDAA Health Storylines app, and click on theRead More

[Continue reading…]

Report by NAMI on State Mental Health Legislation 2015 – Trends, Themes & Effective Practices

National Alliance on Mental Health (NAMI) report, State Mental Health Legislation: Trends, Themes and Effective Practices, highlights the good and bad news in states’ approaches to mental health. The good news is that in 2015, 35 states adopted one or more measures that NAMI applauds with a Gold Star—and five states passed model legislation. TheRead More

[Continue reading…]

High Benzodiazepine Use for Schizophrenia Increases Risk of Death

Chronic, high-dose use of benzodiazepines among patients with schizophrenia appears to be associated with a markedly higher overall mortality rate than is seen in patients with schizophrenia who have not been exposed to benzodiazepines, according to a report in AJP in Advance. The report also found a lower overall mortality rate among patients with schizophrenia who received antipsychotics and/or antidepressants.Read More

[Continue reading…]